Vitalex Biosciences
Private Company
Funding information not available
Overview
Vitalex Biosciences is a private, pre-revenue biotech focused on innovative solutions for serious fungal and bacterial infections. Its core assets include a dual-antigen vaccine targeting Candida species and Gram-negative bacteria, and a monoclonal antibody for mucormycosis, both supported by over $10 million in non-dilutive NIH funding. The company leverages the deep scientific expertise of its founder, Dr. Ashraf Ibrahim, a recognized leader in fungal pathogenesis, and a small team with experience in research, manufacturing, and corporate law.
Technology Platform
Immunotherapeutic platform targeting key virulence factors (e.g., CotH protein) and dual-antigen vaccine design for broad-spectrum protection against fungal and bacterial pathogens.
Opportunities
Risk Factors
Competitive Landscape
The vaccine space for hospital-acquired infections is competitive, with larger firms and biotechs pursuing various targets. The mucormycosis therapeutic space is less crowded but targets a small patient population, which may limit commercial interest from large partners despite the high unmet need.